查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1971150

非酒精性脂肪性肝炎 (NASH) 市場分析及預測（至 2035 年）：按類型、產品類型、服務、技術、應用、最終用戶、階段、模式、組件、解決方案分類

Non-Alcoholic Steatohepatitis (NASH) Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Stage, Mode, Component, Solutions
出版日期: | 出版商: Global Insight Services | 英文 401 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

非酒精性脂肪性肝炎 (NASH) 市場預計將從 2024 年的 83.6 億美元成長至 2034 年的 1,112.6 億美元，複合年成長率約為 29.5%。 NASH 市場涵蓋針對脂肪堆積引起的肝臟發炎和損傷的治療方法，但不包括酒精相關原因。肥胖和糖尿病發病率的上升推動了這個快速成長的細分市場，促使研發部門對新型藥物（例如 FXR促效劑和抗纖維化藥物）進行大量投資。隨著人們對 NASH 的認知不斷提高以及診斷技術的進步，該市場呈現出成長勢頭，為藥物創新提供了盈利的機會。

由於人們對肝臟相關疾病的認知不斷提高，非酒精性脂肪性肝炎 (NASH) 市場預計將迎來顯著成長。在治療領域，藥物細分市場成長最為迅猛，其中以抗纖維化和代謝藥物為主的治療方法展現出良好的療效。 FXR促效劑和 PPAR促效劑等創新藥物類別備受關注，反映了它們在疾病發病機制方面的潛力。診斷領域也呈現強勁成長，其中非侵入性檢測因其對患者的友善性和準確性主導。在各種診斷方法中，彈性成像等能夠精確評估肝纖維化的成像技術已成為第二大細分市場。對早期檢測和個人化醫療的日益重視正在推動生物標記發現的進步。主要產業參與者之間的聯合研究舉措和策略聯盟正在加速創新。隨著市場的不斷發展，數位健康技術的整合有望改善患者管理和治療依從性。

市場區隔
類型 治療和診斷藥物
產品 藥品、生物製藥和營養補充劑
服務 臨床試驗、諮詢服務和監管服務
科技 生物技術、基因組學和蛋白​​質組學
應用 切片檢查、影像學技術和生物標記檢測
最終用戶 醫院、研究機構、製藥公司
步 臨床前研究、I期臨床試驗、II期臨床試驗、III期臨床試驗
實施例 侵入性、非侵入性
成分 活性成分、添加劑
治療方法 生活型態改變、藥物治療與外科手術

市場概況：

非酒精性脂肪性肝炎 (NASH) 市場正經歷市場佔有率、定價策略和新產品上市方面的動態變化。主要製藥公司正策略性地強化產品系列，以獲取更大的市場佔有率。價格競爭仍然激烈，並受到不斷湧入市場的創新治療方案的影響。研發的進步推動著新產品的頻繁上市。這些創新旨在滿足未被滿足的醫療需求，並提供有前景的治療方案。該市場的特點是擁有強大的藥物研發管線，其中包括多個處於後期臨床試驗階段的候選藥物。 NASH 市場競爭異常激烈，主要參與者都在爭奪主導。基準研究表明，策略聯盟和夥伴關係關係至關重要。監管的影響也至關重要，北美和歐洲的監管機構制定了嚴格的指導方針，塑造市場動態。獲得監管部門的核准是影響市場准入和擴張的關鍵里程碑。不斷變化的醫療保健政策會影響藥品定價和報銷，這進一步加劇了競爭格局的複雜性。

主要趨勢和促進因素：

非酒精性脂肪性肝炎 (NASH) 市場正經歷顯著成長，其主要促進因素是肥胖和糖尿病盛行率的不斷上升。這些疾病是 NASH 的主要風險因素，並導致全球發病率不斷攀升。診斷技術的進步是關鍵趨勢，使得 NASH 的早期準確檢測成為可能。這一點至關重要，因為早期介入可以顯著改變疾病進展和患者預後。製藥公司正大力投資研發，以發現有效的治療方法。開發平臺十分強大，眾多藥物正處於不同的臨床試驗階段。研發活動的活性化是市場擴張的關鍵驅動力。此外，生技公司與學術機構之間的合作也不斷加強，促進了創新並加速了藥物研發進程。肝臟健康和 NASH 的宣傳活動日益受到關注，有助於提高診斷率。同時，人們也越來越重視將生活方式介入納入綜合治療方案。在醫療基礎設施不斷完善、先進診斷技術普及程度不斷提高的發展中地區，存在著許多機會。能夠提供經濟高效且擴充性解決方案的公司將在這些新興市場中獲得競爭優勢。

限制與挑戰：

非酒精性脂肪性肝炎 (NASH) 市場面臨許多重大限制和挑戰。其中一項主要挑戰是 NASH 診斷的複雜性，通常需要進行侵入性肝臟切片檢查，這阻礙了廣泛篩檢和早期發現。此外，對此疾病病理生理機制的了解有限，也使得標靶治療的研發更加複雜，並延長了藥物核准流程。缺乏有效的生物標記也為市場帶來挑戰，導致難以監測疾病進展和治療效果。此外，潛在治療方法的高成本可能會限制患者獲得治療的機會，並阻礙市場擴張，尤其是在中低收入國家。監管障礙也是一大挑戰，嚴格的核准流程和國際監管差異可能會延緩新治療方法的推廣應用。最後，來自替代療法和生活方式干涉措施的競爭也構成威脅，因為患者和醫療服務提供者可能會選擇成本更低或侵入性更小的治療方案。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 治療藥物
    • 診斷試劑
  • 市場規模及預測：依產品分類
    • 製藥
    • 生物製藥
    • 營養保健品
  • 市場規模及預測：依服務分類
    • 臨床試驗
    • 諮詢服務
    • 監管服務
  • 市場規模及預測：依技術分類
    • 生物技術
    • 基因組學
    • 蛋白質體學
  • 市場規模及預測：依應用領域分類
    • 切片檢查
    • 診斷影像技術
    • 生物標記檢測
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 研究所
    • 製藥公司
  • 市場規模及預測：依階段分類
    • 臨床前
    • 第一階段
    • II 期研究
    • III期臨床試驗
  • 市場規模及預測：按模式
    • 侵入性檢查
    • 非侵入性
  • 市場規模及預測：依組件分類
    • 原料藥
    • 添加劑
  • 市場規模及預測：按解決方案分類
    • 生活方式改善
    • 藥物治療
    • 手術介入

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Intercept Pharmaceuticals
  • Genfit
  • Madrigal Pharmaceuticals
  • Galmed Pharmaceuticals
  • Viking Therapeutics
  • Akero Therapeutics
  • Terns Pharmaceuticals
  • 89bio
  • Enyo Pharma
  • Inventiva
  • NorthSea Therapeutics
  • NGM Biopharmaceuticals
  • Gilead Sciences
  • Allergan
  • Conatus Pharmaceuticals
  • Zydus Cadila
  • Hepion Pharmaceuticals
  • Galectin Therapeutics
  • Alnylam Pharmaceuticals
  • Dicerna Pharmaceuticals

第9章：關於我們

簡介目錄
Product Code: GIS33177

Non-Alcoholic Steatohepatitis (NASH) Market is anticipated to expand from $8.36 billion in 2024 to $111.26 billion by 2034, growing at a CAGR of approximately 29.5%. The Non-Alcoholic Steatohepatitis (NASH) Market encompasses therapeutics targeting liver inflammation and damage due to fat accumulation, excluding alcohol-related causes. This burgeoning sector is driven by rising obesity and diabetes rates, with significant R&D investment in novel drug classes like FXR agonists and anti-fibrotic agents. The market is poised for growth as awareness and diagnostic advancements increase, offering lucrative opportunities for pharmaceutical innovation.

The Non-Alcoholic Steatohepatitis (NASH) Market is poised for significant growth, driven by rising awareness and increasing incidence of liver-related disorders. Within the treatment segment, the pharmaceuticals sub-segment is the top performer, with a focus on anti-fibrotic and metabolic drugs showing promising therapeutic outcomes. Innovative drug classes such as FXR agonists and PPAR agonists are gaining traction, reflecting their potential in addressing disease pathology. The diagnostics segment is also witnessing robust growth, with non-invasive tests leading due to their patient-friendly nature and accuracy. Among diagnostics, imaging techniques like elastography are emerging as the second highest performing sub-segment, offering precise liver fibrosis assessment. The growing emphasis on early detection and personalized medicine is fostering advancements in biomarker discovery. Collaborative research initiatives and strategic partnerships among key industry players are accelerating innovation. As the market evolves, the integration of digital health technologies is expected to enhance patient management and treatment adherence.

Market Segmentation
TypeTherapeutics, Diagnostics
ProductPharmaceuticals, Biologics, Nutraceuticals
ServicesClinical Trials, Consulting Services, Regulatory Services
TechnologyBiotechnology, Genomics, Proteomics
ApplicationLiver Biopsy, Imaging Techniques, Biomarker Assays
End UserHospitals, Research Institutes, Pharmaceutical Companies
StagePreclinical, Phase I, Phase II, Phase III
ModeInvasive, Non-Invasive
ComponentActive Pharmaceutical Ingredients, Excipients
SolutionsLifestyle Modification, Pharmacotherapy, Surgical Intervention

Market Snapshot:

The Non-Alcoholic Steatohepatitis (NASH) market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Leading pharmaceutical companies are strategically enhancing their portfolios to capture greater market share. Pricing remains competitive, influenced by innovative treatment options entering the market. New product launches are frequent, driven by advancements in research and development. These innovations aim to address unmet clinical needs, offering promising therapeutic solutions. The market is characterized by a robust pipeline of drugs, with several candidates in advanced stages of clinical trials. Competition within the NASH market is intense, with key players vying for dominance. Benchmarking reveals a landscape where strategic collaborations and partnerships are pivotal. Regulatory influences play a crucial role, with agencies in North America and Europe setting stringent guidelines that shape market dynamics. Regulatory approvals are critical milestones that impact market entry and expansion. The competitive environment is further complicated by the need for compliance with evolving healthcare policies, which affect drug pricing and reimbursement.

Geographical Overview:

The Non-Alcoholic Steatohepatitis (NASH) market is witnessing notable growth across various regions, each showcasing unique opportunities. North America leads the market, driven by a high prevalence of obesity and diabetes, which are major risk factors for NASH. The region's advanced healthcare infrastructure and strong focus on research and development further bolster its market position. Europe follows closely, with increasing awareness and early diagnosis initiatives contributing to market growth. The region's emphasis on innovative therapeutics and supportive regulatory frameworks enhances its appeal. In the Asia Pacific, the market is expanding rapidly, fueled by rising healthcare expenditure and a growing patient pool. Countries like China and India are emerging as key growth pockets due to increasing prevalence rates and improving healthcare access. Latin America and the Middle East & Africa present emerging opportunities. Latin America's market is driven by rising healthcare investments, while the Middle East & Africa are recognizing the significance of addressing NASH to mitigate associated healthcare burdens.

Key Trends and Drivers:

The Non-Alcoholic Steatohepatitis (NASH) market is experiencing substantial growth driven by increasing prevalence of obesity and diabetes. These conditions are major risk factors for NASH, leading to a rising incidence rate globally. Key trends include advancements in diagnostic technologies, enabling earlier and more accurate detection of NASH. This is crucial as early-stage intervention can significantly alter disease progression and patient outcomes. Pharmaceutical companies are investing heavily in research and development to discover effective therapeutic options. The pipeline is robust, with numerous drugs in various stages of clinical trials. This surge in R&D activity is a critical driver of market expansion. Additionally, there is a growing collaboration between biotech firms and academic institutions, fostering innovation and accelerating drug development timelines. Awareness campaigns about liver health and NASH are gaining traction, contributing to increased diagnosis rates. This is coupled with a greater emphasis on lifestyle modifications as part of comprehensive treatment plans. Opportunities abound in developing regions where healthcare infrastructure is improving, and access to advanced diagnostics is expanding. Companies that can provide cost-effective and scalable solutions stand to gain a competitive edge in these emerging markets.

Restraints and Challenges:

The Non-Alcoholic Steatohepatitis (NASH) market encounters several significant restraints and challenges. A primary challenge is the complexity of accurately diagnosing NASH, which often requires invasive liver biopsies that deter widespread screening and early detection. Additionally, there is a limited understanding of the disease's pathophysiology, complicating the development of targeted therapies and prolonging the drug approval process. The market also suffers from a lack of effective biomarkers, hindering the ability to monitor disease progression and treatment efficacy. Furthermore, the high cost of potential therapies may restrict access, especially in low- and middle-income countries, thus limiting market expansion. Regulatory hurdles present another challenge, as stringent approval processes and varying international regulations can delay the introduction of new treatments. Lastly, competition from alternative therapies and lifestyle interventions poses a threat, as patients and healthcare providers may opt for less costly or invasive options.

Key Players:

Intercept Pharmaceuticals, Genfit, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Viking Therapeutics, Akero Therapeutics, Terns Pharmaceuticals, 89bio, Enyo Pharma, Inventiva, NorthSea Therapeutics, NGM Biopharmaceuticals, Gilead Sciences, Allergan, Conatus Pharmaceuticals, Zydus Cadila, Hepion Pharmaceuticals, Galectin Therapeutics, Alnylam Pharmaceuticals, Dicerna Pharmaceuticals

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Mode
  • 2.9 Key Market Highlights by Component
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Therapeutics
    • 4.1.2 Diagnostics
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Pharmaceuticals
    • 4.2.2 Biologics
    • 4.2.3 Nutraceuticals
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Clinical Trials
    • 4.3.2 Consulting Services
    • 4.3.3 Regulatory Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Biotechnology
    • 4.4.2 Genomics
    • 4.4.3 Proteomics
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Liver Biopsy
    • 4.5.2 Imaging Techniques
    • 4.5.3 Biomarker Assays
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Research Institutes
    • 4.6.3 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Preclinical
    • 4.7.2 Phase I
    • 4.7.3 Phase II
    • 4.7.4 Phase III
  • 4.8 Market Size & Forecast by Mode (2020-2035)
    • 4.8.1 Invasive
    • 4.8.2 Non-Invasive
  • 4.9 Market Size & Forecast by Component (2020-2035)
    • 4.9.1 Active Pharmaceutical Ingredients
    • 4.9.2 Excipients
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Lifestyle Modification
    • 4.10.2 Pharmacotherapy
    • 4.10.3 Surgical Intervention

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Stage
      • 5.2.1.8 Mode
      • 5.2.1.9 Component
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Stage
      • 5.2.2.8 Mode
      • 5.2.2.9 Component
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Stage
      • 5.2.3.8 Mode
      • 5.2.3.9 Component
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Stage
      • 5.3.1.8 Mode
      • 5.3.1.9 Component
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Stage
      • 5.3.2.8 Mode
      • 5.3.2.9 Component
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Stage
      • 5.3.3.8 Mode
      • 5.3.3.9 Component
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Stage
      • 5.4.1.8 Mode
      • 5.4.1.9 Component
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Stage
      • 5.4.2.8 Mode
      • 5.4.2.9 Component
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Stage
      • 5.4.3.8 Mode
      • 5.4.3.9 Component
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Stage
      • 5.4.4.8 Mode
      • 5.4.4.9 Component
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Stage
      • 5.4.5.8 Mode
      • 5.4.5.9 Component
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Stage
      • 5.4.6.8 Mode
      • 5.4.6.9 Component
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Stage
      • 5.4.7.8 Mode
      • 5.4.7.9 Component
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Stage
      • 5.5.1.8 Mode
      • 5.5.1.9 Component
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Stage
      • 5.5.2.8 Mode
      • 5.5.2.9 Component
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Stage
      • 5.5.3.8 Mode
      • 5.5.3.9 Component
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Stage
      • 5.5.4.8 Mode
      • 5.5.4.9 Component
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Stage
      • 5.5.5.8 Mode
      • 5.5.5.9 Component
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Stage
      • 5.5.6.8 Mode
      • 5.5.6.9 Component
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Stage
      • 5.6.1.8 Mode
      • 5.6.1.9 Component
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Stage
      • 5.6.2.8 Mode
      • 5.6.2.9 Component
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Stage
      • 5.6.3.8 Mode
      • 5.6.3.9 Component
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Stage
      • 5.6.4.8 Mode
      • 5.6.4.9 Component
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Stage
      • 5.6.5.8 Mode
      • 5.6.5.9 Component
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Intercept Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Genfit
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Madrigal Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Galmed Pharmaceuticals
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Viking Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Akero Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Terns Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 89bio
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Enyo Pharma
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Inventiva
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 NorthSea Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 NGM Biopharmaceuticals
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Gilead Sciences
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Allergan
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Conatus Pharmaceuticals
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Zydus Cadila
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Hepion Pharmaceuticals
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Galectin Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Alnylam Pharmaceuticals
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Dicerna Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us